Sotrovimab Cuts Risk for COVID-19 Progression in High-Risk Patients
Interim analysis shows lower risk for progression with sotrovimab versus placebo among high-risk patients with mild-to-moderate COVID-19
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.